Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237735 | 0.87 | KMT2A (0.45) | KMT2AALDH1A1MEN1MIFHTT | |
| SCHEMBL8029164 | 0.74 | ALDH1A1 (0.50) | KMT2AALDH1A1MEN1MIFHTT | |
| SCHEMBL8852224 | 0.72 | MIF (0.39) | KMT2AATML3MBTL1ALDH1A1MEN1 | |
| SCHEMBL49576 | 0.71 | LTA4H (0.38) | KMT2AALDH1A1MEN1 | |
| SCHEMBL10502034 | 0.71 | ALDH1A1 (0.38) | KMT2AALDH1A1MEN1HTTTSHR | |
| SCHEMBL9794657 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL12943093 | 0.71 | ALDH1A1 (0.44) | KMT2AALDH1A1MEN1MIFHTT | |
| SCHEMBL28495899 | 0.71 | ALDH1A1 (0.44) | KMT2AALDH1A1MEN1MIFHTT | |
| SCHEMBL8974972 | 0.71 | ALDH1A1 (0.37) | KMT2AL3MBTL1ALDH1A1MEN1HTT | |
| SCHEMBL17985089 | 0.71 | KMT2A (0.35) | KMT2AATML3MBTL1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710089-B2 | ATHEROSCLEROSIS; CARDIOVASCULAR DISORDERS; ANTICHOLESTEROL AGENTS | PHARMACIA CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-6696472-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6677382-B1 | HALOGENATED OXYAMINES, USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS, AND AS ANTILIPEMIC AGENTS | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-19 | — | — | US | disclosed |
| US-6458849-B1 | METHOD OF TREATING OR PREVENTING A CEIP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND FOR STROKES | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | KMT2A 2608/4885ATM 3912/4885L3MBTL1 1616/4885 |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | KMT2A 2608/4885ATM 3912/4885L3MBTL1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.